Phase III Trial on the Efficacy and Safety of Methylbardoxolone in Patients with Autosomal Dominant Polycystic Kidney Disease. FALCON

COMMERCIAL CLINICAL TRIAL

Home · TEC14-Human Reproduction and Hereditary and Complex Diseases

Clinical trial information

Promoter: REATA PHARMACEUTICALS INC
Phase: III
Execution start: 02/03/2021
End of execution: 30/06/2023
IP: RAFAEL JOSE ESTEBAN DE LA ROSA